Moderna, Inc. (FRA:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 9.26B |
| Revenue (ttm) | 3.13B |
| Net Income (ttm) | -3.44B |
| Shares Out | n/a |
| EPS (ttm) | -8.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423 |
| Average Volume | 22,140 |
| Open | 23.84 |
| Previous Close | 23.83 |
| Day's Range | 23.67 - 24.44 |
| 52-Week Range | 20.18 - 155.50 |
| Beta | n/a |
| RSI | 42.46 |
| Earnings Date | May 1, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
More Downside For Moderna Before The Breakthrough
33 Stocks That Could Rally 50% or More This Year
Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.
Learn Investing: The Income Statement
How to Read a Company’s Income Statement: The Essentials (With Market Context and Real-World Examples) The income statement, also known as the profit and loss statement, is one of the three main finan...
Short bets against S&P 500 healthcare stock rise in March; MRNA stays top shorted
In March, short sellers collectively increased their negative bets on the broader healthcare industry. Read more details here.
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...
Spotlight on Moderna: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna . Looking at options history for Moderna (NASDAQ: MRNA) we detected 13 trades. If we consider the specifics of ea...
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022
CureVac's 2024 Financial Results & Key Updates: April 10 Reveal
Discover CureVac's 2024 financial insights on April 10, 2025, as the mRNA pioneer shares its global achievements and future outlook. Jetzt den vollständigen Artikel lesen
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter
Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as Ireland.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Moderna (MRNA) Shares Drop to Five-Year Low Amid Leadership Change
Moderna (MRNA) Shares Drop to Five-Year Low Amid Leadership Change
Nvidia, Moderna, Lucid, Dominari Holdings, Tesla: Why These 5 Stocks Are On Investors' Radars Today (CORRECTED)
Editor’s Note: This story has been updated to correct an error where “Nasdaq 100” was mistakenly used instead of “Nasdaq.” The stock market faced a challenging day as risk sentiment remained under pre...
:max_bytes(150000):strip_icc():format(jpeg)/MRNAChart-23dc2f45452a42e7b9cdb1e5d3ae71e0.jpg)
Watch These Moderna Price Levels as Stock Sinks to 5-Year Low
Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key pri...
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1571852180-a1d881f3c601497ebe9bbf366efac663.jpg)
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Resignation of FDA Vaccine Official
The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of reciprocal tariffs later this week.
Moderna (MRNA) Stock Drops Amid FDA Official's Departure
Moderna (MRNA) Stock Drops Amid FDA Official's Departure
S&P 500 recoups losses, Dow rises as volatile March ends; Newsmax surges, Moderna tanks
Investors were nervous about US President Donald Trump's tariff plans, which caused the S&P 500 to fall on Monday and enter correction territory. However, the index recovered its losses from earlier ...
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
